Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
BiologicsGene Therapeutics & RNAi

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1731915

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1731915

Viral Vectors for Non-Human Primates

PUBLISHED:
PAGES: 473 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Viral Vectors for Non-Human Primates Market to Reach US$265.3 Million by 2030

The global market for Viral Vectors for Non-Human Primates estimated at US$156.3 Million in the year 2024, is expected to reach US$265.3 Million by 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Adenoviral Vectors, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$100.9 Million by the end of the analysis period. Growth in the Adeno-Associated Vectors segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.6 Million While China is Forecast to Grow at 13.0% CAGR

The Viral Vectors for Non-Human Primates market in the U.S. is estimated at US$42.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$54.8 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.3% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global "Viral Vectors for Non-Human Primates" Market - Key Trends & Drivers Summarized

Why Are Viral Vectors Gaining Traction in Primate-Based Biomedical Research?

The increasing use of non-human primates (NHPs) in advanced biomedical and neurological research is accelerating the demand for highly efficient viral vectors. These vectors are indispensable tools for delivering genetic material into host cells, enabling researchers to manipulate gene expression with precision. In the context of NHPs, viral vectors are used for studying complex brain functions, neurodegenerative diseases, and cognitive behaviors that closely mimic those in humans. The species similarity of NHPs to humans in terms of neuroanatomy and physiology makes them ideal models for translational research. Adeno-associated viruses (AAVs), lentiviruses, and herpes simplex viruses are among the most commonly used vectors due to their stable expression, high infectivity, and reduced immunogenic responses. The recent surge in interest for optogenetics and gene therapy approaches further cements the role of viral vectors as essential instruments in preclinical studies involving NHPs. The precision required in targeting specific brain regions or genetic sequences in these models has prompted a shift toward tailor-made vectors with neuron-specific promoters and tissue tropism. Consequently, academic institutions, pharmaceutical companies, and biotech firms are investing heavily in viral vector development tailored to primate research.

How Are Regulatory Shifts and Ethical Standards Influencing the Landscape?

As viral vector applications in non-human primates expand, global regulatory frameworks are evolving to ensure both scientific integrity and ethical compliance. Regulatory bodies such as the NIH, EMA, and FDA have introduced stringent guidelines that govern the use of NHPs and viral vectors in laboratory settings. These include detailed protocols for biosafety, vector containment, and animal welfare. Ethical considerations are also playing a significant role in shaping research design, pushing stakeholders toward minimal invasiveness and refined vector delivery systems. The 3Rs principle-Replacement, Reduction, and Refinement-is influencing the selection of viral vectors that offer higher transduction efficiency with lower doses, reducing the overall burden on animal subjects. Concurrently, cross-disciplinary collaborations between neuroscientists, virologists, and bioengineers are catalyzing innovations in vector design that are both more effective and ethically sound. The establishment of primate-specific viral vector repositories and open-access platforms is also promoting standardized practices globally. Additionally, increased transparency in data reporting and ethical review processes has begun influencing the choices researchers make when selecting viral vectors for NHP studies, indicating a shift toward greater accountability and sustainability in the field.

What Technological Breakthroughs Are Pushing This Field Forward?

Technological innovations are dramatically redefining what is possible in the use of viral vectors for non-human primate research. Advanced vector engineering techniques, such as CRISPR-based genome editing and single-cell sequencing, are enabling more targeted and efficient genetic manipulations. Customizable AAV capsids designed through directed evolution now allow for selective targeting of specific neuronal populations, even within deep brain structures. High-throughput screening technologies have accelerated the discovery of novel vector serotypes with enhanced specificity and minimized immune responses. Simultaneously, improvements in vector manufacturing processes-such as scalable production in suspension cultures and purification via chromatography-are making it feasible to produce clinical-grade vectors suitable for large-scale studies. Moreover, innovations in delivery methods, including stereotactic injection, focused ultrasound-mediated delivery, and minimally invasive catheter-based systems, have significantly improved the precision of vector deployment in primates. AI-driven modeling tools are also being employed to predict vector behavior, optimize dosages, and assess off-target effects. These advances are not only expanding the scope of basic and applied research but are also paving the way for translational studies that could bridge the gap between animal models and human clinical trials.

What’s Powering the Surge in the Viral Vectors for Non-Human Primates Market?

The growth in the viral vectors for non-human primates market is driven by several factors closely tied to evolving research paradigms, technological advancements, and end-user demands. A primary driver is the increasing reliance on NHPs in neurodegenerative disease modeling, where traditional rodent models fall short. This has created a strong demand for precision tools like viral vectors that can facilitate functional studies of complex brain networks. The expansion of gene therapy pipelines by pharmaceutical and biotech companies is another major catalyst, as these firms require robust preclinical validation in primate models before progressing to human trials. Academic and government research institutions are also ramping up funding for neuroscience and behavioral research that necessitates the use of viral vectors in NHPs. There is a rising emphasis on personalized medicine and biomarker discovery, which further fuels the need for advanced in vivo models enabled by viral vectors. Additionally, the trend toward open science and data sharing has led to collaborative consortia that focus on creating standardized, high-performance vectors for NHP use. Lastly, advancements in primate-specific immunosuppressive strategies have minimized vector rejection, making these tools more viable and reliable in long-term studies. Together, these factors are converging to push the global market into a phase of rapid expansion and diversification.

SCOPE OF STUDY:

The report analyzes the Viral Vectors for Non-Human Primates market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Vector Type (Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors, Other Vector Types); Therapeutic Area (Genetic Disorders, Infectious Diseases, Oncological Disorders, Other Therapeutic Areas); Application (Gene Therapy, Vaccine Research); End-Use (Pharma & Biotech Companies, Academic & Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • 4D Molecular Therapeutics
  • Andelyn Biosciences
  • Barinthus Biotherapeutics
  • Beacon Therapeutics
  • Biovian Oy
  • Catalent Pharma Solutions
  • Charles River Laboratories
  • CRISPR Therapeutics
  • FinVector Oy
  • Fujifilm Diosynth Biotechnologies
  • Genezen
  • Lonza Group AG
  • Merck KGaA
  • Neuracle Genetics Inc.
  • Oxford Biomedica
  • REGENXBIO Inc.
  • Rocket Pharmaceuticals, Inc.
  • SIRION Biotech GmbH
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP34488

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Viral Vectors for Non-Human Primates - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Use of NHP Models in Neurological Research Spurs Demand for Viral Vectors
    • Rising Investment in Gene Therapy Expands Addressable Market Opportunity
    • Regulatory Push for Ethical NHP Use Strengthens Business Case for Viral Vector Customization
    • Advances in Vector Tropism Tailoring Drives Adoption in Preclinical Studies
    • Growing Complexity of Disease Models Accelerates Demand for Novel Vector Systems
    • Outsourcing Trends in Biopharma R&D Propel Growth in Specialized Vector Services
    • Shift Towards Non-Invasive Delivery Methods Spurs Innovation in Viral Vector Design
    • Collaborative Research Ecosystems Sustain Growth in Translational NHP Research
    • Heightened Focus on Zoonotic Safety Issues Throws the Spotlight on Regulatory Compliance
    • Integration of AI in Vector Optimization Drives Efficiency Gains
    • Emerging Applications in Vaccine R&D Expand Market Scope for Viral Vectors
    • Funding Initiatives by Global Health Agencies Strengthen Long-Term Market Outlook
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Viral Vectors for Non-Human Primates Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adeno-Associated Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adeno-Associated Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Adeno-Associated Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lentiviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lentiviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Lentiviral Vectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Vector Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Vector Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Oncological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Oncological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • JAPAN
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • CHINA
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • EUROPE
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • FRANCE
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • GERMANY
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • INDIA
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Viral Vectors for Non-Human Primates by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030
  • AFRICA
    • Viral Vectors for Non-Human Primates Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Viral Vectors for Non-Human Primates by Vector Type - Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by Vector Type - Percentage Breakdown of Value Sales for Adenoviral Vectors, Adeno-Associated Vectors, Retroviral Vectors, Lentiviral Vectors and Other Vector Types for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Viral Vectors for Non-Human Primates by Application - Gene Therapy and Vaccine Research Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by Application - Percentage Breakdown of Value Sales for Gene Therapy and Vaccine Research for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Viral Vectors for Non-Human Primates by End-Use - Pharma & Biotech Companies and Academic & Research Institutes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies and Academic & Research Institutes for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Viral Vectors for Non-Human Primates by Therapeutic Area - Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Viral Vectors for Non-Human Primates by Therapeutic Area - Percentage Breakdown of Value Sales for Genetic Disorders, Infectious Diseases, Oncological Disorders and Other Therapeutic Areas for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!